Have any questions? 706-721-6582 or cts@augusta.edu
- KRT-232-117: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)
Clinical Trial
KRT-232-117: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)
This is a research study to test a new drug called KRT-232 that is not approved by the Food and Drug Administration (FDA) to treat Chroic Myeloid Leukemia (CML). We are looking to see if the drug works on your cancer, if the drug is safe and what type of treatment is better. Prior to entry into this study, you will also need to be taking either nilotinib or dasatinib. The combination of KRT-232 with nilotinib or dasatinib is also investigational.
Eligibility Criteria
- Male or female, aged 18 years or older Subjects with confirmed relapsed/refractory Ph+ Chronic Myeloid Leukemia (CML) Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
RESEARCH. INNOVATION. DISCOVERY.